As we recover from Halloween and prepare for Thanksgiving, take a moment to check out some recent FDA announcements.
A treatment for a rare tumor, occurring mostly in older population, is currently in phase 3 trials. FDA recently granted the developers of the drug a breakthrough designation.
Vascular EDS is rare, potentially fatal, and difficult to treat. Acer is trying to change this.
Good news for the LGS community! The FDA just approved a new medicine for this rare form of epilepsy.
Because children with progeria age faster, they generally pass away in their teenage years. A new possible treatment option was just given a designation to help speed it along.